vs
ANI PHARMACEUTICALS INC（ANIP）とSTRATTEC SECURITY CORP（STRT）の財務データ比較。上の社名をクリックして会社を切り替えられます
ANI PHARMACEUTICALS INCの直近四半期売上が大きい（$247.1M vs $137.5M、STRATTEC SECURITY CORPの約1.8倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 3.6%、差は7.5%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 5.9%）。ANI PHARMACEUTICALS INCの直近四半期フリーキャッシュフローが多い（$29.1M vs $11.3M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 7.7%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
STRATTECセキュリティコーポレーションは、自動車用機械式・電子式ロック、キー、パッシブエントリーシステムなどのセキュリティアクセス製品を設計・製造・販売しています。主な顧客は世界の自動車OEM、大型車両メーカー、自動車アフターマーケット事業者で、北米、欧州、アジア太平洋地域で事業を展開しています。
ANIP vs STRT — 直接比較
損益計算書 — Q4 FY2025 vs Q2 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $137.5M |
| 純利益 | $27.5M | $4.9M |
| 粗利率 | — | 16.5% |
| 営業利益率 | 14.1% | 3.5% |
| 純利益率 | 11.1% | 3.6% |
| 売上前年比 | 29.6% | 5.9% |
| 純利益前年比 | 367.5% | 275.1% |
| EPS（希薄化後） | $1.14 | $1.20 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $137.5M | ||
| Q3 25 | $227.8M | $152.4M | ||
| Q2 25 | $211.4M | $152.0M | ||
| Q1 25 | $197.1M | $144.1M | ||
| Q4 24 | $190.6M | $129.9M | ||
| Q3 24 | $148.3M | $139.1M | ||
| Q2 24 | $138.0M | — | ||
| Q1 24 | $137.4M | $140.8M |
| Q4 25 | $27.5M | $4.9M | ||
| Q3 25 | $26.6M | $8.5M | ||
| Q2 25 | $8.5M | $8.3M | ||
| Q1 25 | $15.7M | $5.4M | ||
| Q4 24 | $-10.3M | $1.3M | ||
| Q3 24 | $-24.2M | $3.7M | ||
| Q2 24 | $-2.3M | — | ||
| Q1 24 | $18.2M | $1.5M |
| Q4 25 | — | 16.5% | ||
| Q3 25 | — | 17.3% | ||
| Q2 25 | — | 16.7% | ||
| Q1 25 | — | 16.0% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | — | 13.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 10.4% |
| Q4 25 | 14.1% | 3.5% | ||
| Q3 25 | 15.9% | 6.9% | ||
| Q2 25 | 6.6% | 5.6% | ||
| Q1 25 | 13.3% | 4.9% | ||
| Q4 24 | -2.3% | 1.6% | ||
| Q3 24 | -13.8% | 3.6% | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | 14.8% | 1.4% |
| Q4 25 | 11.1% | 3.6% | ||
| Q3 25 | 11.7% | 5.6% | ||
| Q2 25 | 4.0% | 5.4% | ||
| Q1 25 | 8.0% | 3.7% | ||
| Q4 24 | -5.4% | 1.0% | ||
| Q3 24 | -16.3% | 2.7% | ||
| Q2 24 | -1.7% | — | ||
| Q1 24 | 13.2% | 1.1% |
| Q4 25 | $1.14 | $1.20 | ||
| Q3 25 | $1.13 | $2.07 | ||
| Q2 25 | $0.36 | $2.02 | ||
| Q1 25 | $0.69 | $1.32 | ||
| Q4 24 | $-0.45 | $0.32 | ||
| Q3 24 | $-1.27 | $0.92 | ||
| Q2 24 | $-0.14 | — | ||
| Q1 24 | $0.82 | $0.37 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $99.0M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $540.7M | $236.8M |
| 総資産 | $1.4B | $392.2M |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $99.0M | ||
| Q3 25 | $262.6M | $90.5M | ||
| Q2 25 | $217.8M | $84.6M | ||
| Q1 25 | $149.8M | $62.1M | ||
| Q4 24 | $144.9M | $42.6M | ||
| Q3 24 | $145.0M | $34.4M | ||
| Q2 24 | $240.1M | — | ||
| Q1 24 | $228.6M | $9.6M |
| Q4 25 | $540.7M | $236.8M | ||
| Q3 25 | $505.8M | $230.5M | ||
| Q2 25 | $436.8M | $221.6M | ||
| Q1 25 | $418.6M | $210.7M | ||
| Q4 24 | $403.7M | $204.5M | ||
| Q3 24 | $405.9M | $203.0M | ||
| Q2 24 | $455.8M | — | ||
| Q1 24 | $452.0M | $193.8M |
| Q4 25 | $1.4B | $392.2M | ||
| Q3 25 | $1.4B | $390.1M | ||
| Q2 25 | $1.3B | $391.5M | ||
| Q1 25 | $1.3B | $387.4M | ||
| Q4 24 | $1.3B | $355.9M | ||
| Q3 24 | $1.3B | $366.9M | ||
| Q2 24 | $920.8M | — | ||
| Q1 24 | $914.5M | $348.5M |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $13.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $11.3M |
| FCFマージンFCF / 売上 | 11.8% | 8.2% |
| 設備投資強度設備投資 / 売上 | 0.5% | 1.9% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 2.81× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $67.8M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $13.9M | ||
| Q3 25 | $44.1M | $11.3M | ||
| Q2 25 | $75.8M | $30.2M | ||
| Q1 25 | $35.0M | $20.7M | ||
| Q4 24 | $15.9M | $9.4M | ||
| Q3 24 | $12.5M | $11.3M | ||
| Q2 24 | $17.4M | — | ||
| Q1 24 | $18.3M | $-309.0K |
| Q4 25 | $29.1M | $11.3M | ||
| Q3 25 | $38.0M | $9.8M | ||
| Q2 25 | $71.8M | $27.2M | ||
| Q1 25 | $32.5M | $19.6M | ||
| Q4 24 | $13.5M | $8.5M | ||
| Q3 24 | $7.7M | $9.3M | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $13.7M | $-2.0M |
| Q4 25 | 11.8% | 8.2% | ||
| Q3 25 | 16.7% | 6.4% | ||
| Q2 25 | 34.0% | 17.9% | ||
| Q1 25 | 16.5% | 13.6% | ||
| Q4 24 | 7.1% | 6.6% | ||
| Q3 24 | 5.2% | 6.7% | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.0% | -1.4% |
| Q4 25 | 0.5% | 1.9% | ||
| Q3 25 | 2.7% | 1.0% | ||
| Q2 25 | 1.9% | 2.0% | ||
| Q1 25 | 1.3% | 0.8% | ||
| Q4 24 | 1.3% | 0.7% | ||
| Q3 24 | 3.2% | 1.5% | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.3% | 1.2% |
| Q4 25 | 1.10× | 2.81× | ||
| Q3 25 | 1.66× | 1.33× | ||
| Q2 25 | 8.87× | 3.65× | ||
| Q1 25 | 2.23× | 3.84× | ||
| Q4 24 | — | 7.16× | ||
| Q3 24 | — | 3.06× | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | -0.21× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
STRT
| Door Handles And Exterior Trim | $35.0M | 25% |
| Power Access Solutions | $34.5M | 25% |
| Keys And Locksets | $26.8M | 19% |
| Latches | $16.3M | 12% |
| User Interface Controls | $12.5M | 9% |
| Aftermarket And Service | $9.4M | 7% |
| Other Product | $3.1M | 2% |
| Related Party | $1.3M | 1% |
